SHR-A2102

DRUG13 trials

Sponsors

Fudan University, Shanghai Hengrui Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Advanced Breast CancerAdvanced Or Metastatic Solid Tumor MalignanciesAdvanced Solid TumorsAdvanced Urothelial CarcinomaBreast CancerBreast NeoplasmHER2-negative Breast CancerHormone Receptor Positive Tumor

Phase 1

Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

RecruitingNCT05701709

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2023-04-06End: 2025-08-31Target: 395Updated: 2025-07-22

A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Or Metastatic Solid Tumor Malignancies

Start: 2023-03-03End: 2025-08-31Target: 252Updated: 2023-03-28

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

RecruitingNCT06417554

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2024-05-13End: 2027-07-31Target: 80Updated: 2024-12-31

A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

RecruitingNCT06589778

Shanghai Hengrui Pharmaceutical Co., Ltd.Non-Small Cell Lung Cancer

Start: 2024-09-27End: 2026-04-30Target: 124Updated: 2024-11-12

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

RecruitingNCT06639347

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Urothelial Carcinoma

Start: 2024-11-04End: 2027-05-31Target: 90Updated: 2024-11-18

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

RecruitingNCT07059221

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start: 2025-07-11End: 2028-03-31Target: 96Updated: 2025-07-22

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruitingNCT07414953

Jiangsu Hansoh Pharmaceutical Co., Ltd.Lung Cancer

Start: 2026-03-30End: 2028-11-30Target: 400Updated: 2026-02-17

Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

RecruitingNCT05076682

Fudan UniversityTriple-negative Breast Cancer

Start: 2022-06-30End: 2027-03-31Target: 80Updated: 2025-12-03

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

RecruitingNCT05594095

Fudan UniversityAdvanced Breast Cancer, Breast Cancer, Breast Neoplasm +2

Start: 2022-12-30End: 2026-12-01Target: 620Updated: 2024-10-04

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

RecruitingNCT06649331

Fudan UniversityAdvanced Breast Cancer, Breast Cancer, HER2-negative Breast Cancer +2

Start: 2024-10-21End: 2027-09-01Target: 160Updated: 2026-03-17

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

RecruitingNCT06895928

Shanghai Hengrui Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2025-03-28End: 2028-12-31Target: 400Updated: 2025-04-22

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

Not yet recruitingNCT07041437

Fudan UniversityAdvanced Breast Cancer

Start: 2025-06-30End: 2027-01-31Target: 48Updated: 2025-06-27

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

RecruitingNCT07229729

Shanghai Hengrui Pharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2025-11-24End: 2029-10-31Target: 300Updated: 2025-12-01

Related Papers

Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.

2025-12-04

Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.

2025-06-25

Abstract P2-09-17: Precision medicine based on similarity network fusion (SNF) subtypes of multi-omics in CDK4/6 inhibitor failed HR+/ HER2- advanced breast cancer: the Linux trial

Clinical Cancer Research2025-06-13

Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors.

Journal of Clinical Oncology2025-05-282 citations

Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.

Journal of Clinical Oncology2025-02-106 citations

Abstract PO1-14-07: Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial)

Cancer Research2024-05-02